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Summary 
We assessed the role of CD40-CD40L,  cytotoxic T  lymphocyte (CTL)A4/CD28-B7s,  and 
CD2-CD48/CD58 lymphocyte costimulatory pathways in the development of mercury chlo- 
ride  (HgC12)-induced autoimmune disease in mice, which is believed to be mediated by T 
helper (Th) subset Th2. Inhibition of CD40-CD40L and CTLA4/CD28-B7s interactions by 
anti-CD40L antibody and soluble CTLA4-immunoglobulin (Ig) fusion protein, respectively, 
abrogated the autoimmune disease without affecting interleukin 4 (IL-4)  production, showing 
the importance of physical contact between T  and B lymphocytes in the Th2-mediated pro- 
cess. In contrast, two anti-CD2 antibodies that have been shown to induce immunosuppres- 
sion of Thl-mediated events exacerbated the autoantibody response and augmented IgG1, IgE, 
and IL-4 production, transforming a mild mesangial glomerulopathy into a severe systemic im- 
mune complex disease. These observations demonstrate that manipulation of lymphocyte ac- 
cessory counterreceptor interactions may affect the course of Th2-associated autoimmune dis- 
ease and suggest that signals resulting from CD2 engagement may play an essential role in the 
regulation of the Thl-Th2 effector equilibrium. 
T 
he  effector mechanisms of the immune response are 
selected by preferential activation of distinct Th sub- 
sets, Thl  and Th2, which express  and respond to distinct 
groups of cytokines. Recent evidence suggests that signals 
generated by specific cell surface counterreceptors that me- 
diate T  cell-APC interactions may be  important in pro- 
moting T  cell differentiation to the Thl or Th2 phenotype 
(1, 2). Several cell surface counterreceptors also provide co- 
stimulatory axes that are implicated in the regulation of T 
and APC/B cell responses as a result of cognate interaction. 
In  particular,  CD40-CD40L,  CD28/CTLA4-B7s,  and 
CD2-CD48/CD58  counterreceptors transduce critical sig- 
nals for the regulation of lymphocyte activation in response 
to antigenic stimulation. 
The receptor-ligand pair composed of the B cell-associ- 
ated receptor CD40 and its T  cell ligand CD40L/gp39 has 
been shown to play a key role in the regulation of T  cell- 
dependent B  cell  proliferation,  antibody production,  and 
isotype  switching  (3). The  CTLA4/CD28-B7s  pathways 
also trigger B  cell responses  (4), but in addition transduce 
essential  costimulatory  signals  for  T  cell  activation  (5). 
CD28 costimulation is important for activation and prolif- 
eration of both Thl  and Th2 clones (6,  7).  The principal 
CD2 ligand is LFA-3 in humans and CD48 in mice (8), a 
glycosyl  phosphatidylinositol-anchored  glycoprotein  ex- 
pressed  on most T  and B  cells.  Engagement of CD2  by 
mAbs as well as by soluble recombinant LFA-3 has been 
shown to have a costimulatory effect on T  cell activation 
(9). Conversely, a potent immunosuppressive effect of anti- 
CD2 mAbs has been observed in vivo, and shown to inhibit 
the Thl-mediated/cytotoxic immune response (10-13). 
In this work, we have examined the implication of lym- 
phocyte  costimulatory pathways  in  the  development  of 
HgC12-induced autoimmune disease in SJL mice. In mice, 
rats,  and rabbits,  mercury, penicillamine, and gold induce 
autoimmune responses  that have several common features, 
including the production of anti-basement membrane and 
antinuclear antibodies, immune complex glomerulonephri- 
tis, and upregulation of MHC class II expression on B lym- 
phocytes (14). In addition, these heavy metal-induced dis- 
orders  present  with  increased  production  of IgG1,  IgE, 
IL-4, and IL-10, with a concomitant decrease in IL-2 and 
IFN-'y production,  consistent with preferential activation 
ofTh2 lymphocytes (15). mAbs to IL-4 prevent some dis- 
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drug-induced autoimmunity is  characterized,  and possibly 
induced, by a Thl-Th2 imbalance (16). 
Materials and Methods 
Animals and Autoimmune Disease Induction.  8-  to  9-wk  SJL/J 
(H-2s) mice were purchased from Jackson Laboratories  (Bar liar- 
bor, ME) and injected subcutaneously with 1.6 mg of HgC12 per 
kilogram of body weight every third day for 4  wk.  The mice 
were bled 2 and 4 wk after the beginning  of the experiments and 
killed at various intervals of time as described.  Six mice were im- 
munized in the hind footpads with "-'25 ~l of 1 mg/mi chicken 
OVA emulsified in CFA (Difco Laboratories,  Detroit, MI) (17). 
The mice were killed 3-5 d after footpad injections. 
Antibodies and Flow Cytometry.  Hamster  anti-mouse CD40L 
(clone MR1) mAb (18), rat anti-mouse CD2 mAbs RM2-1 (19) 
and 12-15 (10), and hamster anti-mouse CD48  (13) were pre- 
pared and purified as previously described.  Rat anti-mouse IL-4 
mAb  11Bll  was  purchased from  the  American Type  Culture 
Collection (ATCC, Rockville, MD); rat anti-mouse IL-10 mAb 
SXC-1 was a kind gift from Drs. S. Reed and Coffman. For im- 
munohistochemical and flow  cytometry studies,  the  following 
antibodies were  used:  rat  anti-mouse Thy  1.2, IL-4  (BVD6- 
24G2),  [L-2  ($4B6),  IFN-',/  (XMG12),  CD45tL/B220  (RA3- 
6B2), CD4 (RM4-5), and CD8 (53-6.7) mAbs from PharMingen 
(San Diego,  CA);  FITC-conjugated rat  anti-mouse IgE  mAb 
from  Serotec/liarlan  Sprague  Dawley  (Indianapolis,  IN);  and 
FITC-rabbit anti-mouse IgG, IgM, and C3 from Cappel Labora- 
tories, Inc. (West Chester,  PA). Purified hamster, human, and rat 
IgGs (Cappel) were used as controls.  FACS  |  analysis for Thyl.2  + 
and CD45R/B220 + cells was performed on Ficoll-separated sple- 
nocytes. 
Immunohistochemistry and Morphology.  Kidney,  heart,  muscle, 
liver, testes, and spleen from mice injected with HgC12, subcuta- 
neous tissue from the footpads  of mice locally immunized, and 
tissues from control mice were removed at sacrifice. Tissues were 
processed  for  immunofluorescence and  electron microscopy as 
previously described  (20). For immunohistochemical  analysis, se- 
rial 4-p~m thick skin and spleen  sections were incubated for  60 
rain at room temperature with biotinylated  primary mAbs and re- 
vealed  by incubation with avidin-biotin horseradish  peroxidase 
complexes  (Vectastain Elite ABC; Vector Laboratories,  Inc., Bur- 
lingame, CA).  Peroxidase  activity  was  detected with 3-amino- 
9-ethylcarbazole.  For  two-color immunocytochemical analysis, 
serial sections single-stained  for cytokines as described above were 
double stained with mAbs to T  and B cell markers,  a secondary 
biotin-conjugated mAb,  and  ExtrAvidin-alkaline phosphatase, 
revealed by 4-chloro-l-naphthol (Sigma Chemical Company, St. 
Louis,  MO).  The sections  were lightly counterstained with he- 
matoxylin. The amount and extent of fluorescence  were semi- 
quantitatively graded on a scale' from 0 to 4 (0, absent;  +, mini- 
mal and focal;  ++,  moderate and focal;  +++,  moderate and 
diffuse; + + + +, marked and diffuse). 
Measurement of Circulating Mouse Total IgG,  IgG1,  IgG2a,  and 
IgE by ELISA.  In all mice included in the experimental groups, 
the levels oflgG, IgG1, IgG2a, and IgE were measured on serum 
samples obtained 0, 15, and 30 d after the beginning  of the exper- 
iments. 96-well microtiter plates were coated overnight at 4~ 
with 1 tzg/ml goat  anti-mouse IgG (Cappel)  or rat anti-mouse 
IgE n-tAb (Harlan Sprague Dawley).  The plates were washed with 
PBS-0.05%  Tween 20  and incubated with  PBS-2%  skimmed 
milk for 30 rain at room temperature. After two washes, serial 1: 
50-1:500 dilutions of mouse sera (100 I*i/well) were added. After 
an overnight incubation at 4~  the plates were washed  and ex- 
posed  for  4  h  to  alkaline  phosphatase-conjugated  goat  anti- 
mouse  IgG  (Sigma), or  rat  anti-mouse IgG1,  IgG2a,  or  IgE 
(PharMingen)  diluted  1:4,000.  After  washing,  p-nitrophenyl 
phosphate  (Sigma) was added,  and the colorimetric reaction was 
read at 405 nm. 
Measurement of Antinucleolar Antibodies  by  Immunofluorescence. 
The titers of anti-nucleolar antibodies (ANolAs) 1 were measured 
by  indirect  immunofluorescence  using  the  HepG-2  human 
hepatoma cell line (ATCC). HepG-2 cells were cultured in 20- 
mm (diameter)  plastic dishes in RPMI 1640 supplemented with 
10% FCS.  Subconfluent cells were fixed in a 4% formaldehyde/ 
PBS  solution, washed  twice with PBS,  and permeabilized with 
0.1% Triton X-100 in PBS for 10 re_in. After three washes with 
PBS, cells were incubated for 1 h at 37~  with serial dilutions of 
the  mouse  sera, washed,  and  incubated with  affinity-purified, 
FITC-conjugated  rabbit anti-mouse IgG (Cappel), diluted 1:500, 
for 45 rain at 37~  The titers were expressed as reciprocal  value 
of the highest  serum dilution that gave an unequivocal positive 
reaction. 
Development and Production of Soluble Recombinant Fusion Pro- 
teins.  Soluble receptor globulins were developed by genetic fu- 
sion of sequences  encoding the  extracellular  region of routine 
CTLA4 to human IgG1  Fc genomic DNA sequences  (21). Syn- 
thetic oligonucleotide primers  complementary to  the  5'  and 3' 
extremities  of the nucleotide sequence encoding the extracellular 
domain ofmurine CTLA4, containing, respectively, an XhoI and 
a  BamHI  restriction  site,  were  used  to  PCg_-amplify  mouse 
CTLA4 from cDNA derived from Con A--stimulated  CTLL-2 
murine cytotoxic T  cells (ATCC). Nucleotide sequences  of the 
primers were the following: forward,  5'-CAC GGG CTC GAG 
ATG  GCT  TGT  CTT  GGA  CTC  CGG  AGG-3';  reverse, 
5'-CAC GGG ATC CCA AAG GAG GAA GTC AGA ATC 
CGG GCA-3'. PCR amplification was performed as described 
(21). Amplified cDNA was subjected to XhoI-BamHI digestion 
and ligated to XhoI-BamliI-cut human IgG1 expression vector. 
Plasmids containing sequences  encoding CTLA4 receptorglobu- 
lin were cotransfected  with a pSVNeo vector into Chinese ham- 
ster ovary (CLIO) cells (ATCC) by electroporation at 250 V/960 IxF 
using a gene pulser (Bio-Rad Labs., Richmond, CA). Transfected 
CHO cells were selected for G418 (GIBCO BILL, Inc., Gaithers- 
burg, MD) resistance. Resistant CHO clones were screened  for 
the production ofCTLA4 Rg by ELISA detection of the human 
IgG Fc domain in the supernatants.  Soluble fusion proteins were 
purified from supematants on protein A-Sepharose,  as previously 
described  (21). A soluble CD8 Rg fusion protein (21) was used as 
a control. 
Statistics.  Statistical analysis, when applicable, was performed 
with Statview IV software (Abacus Concepts, Berkeley,  CA) on a 
Macintosh  SE  computer  (Apple  Computer,  Inc.,  Cupertino, 
CA). Differences  between groups were compared with one-way 
analysis of variance and unpaired t test. 
Results 
HgCl2-induced  Glomendar and Vascular Lesions.  13  groups 
of six to seven mice each were used (Table 1). Five control 
1Abbreviations used in this paper: ANolA, anti-nudeolar antibody; CHO, 
Chinese hamster ovary; PALS, periarteriolar  lymphoid sheath. 
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The  other  four  control  groups  were  treated  with  HgC12 
alone  or HgC12  along with  human  and/or  rodent  IgG, or 
human  CD8-Ig  fusion protein  (CD8Rg),  at the same fre- 
quency and dosage  as the  test groups  (Table  1).  In each of 
the  five test groups,  animals were  treated with  HgC12 and 
received CTLA4 Rg alone, anti-CD40L  mAb MR1  alone, 
a  combination  of CTLA4  Rg  and  MR1,  anti-CD2  mAb 
RM2-1,  anti-CD2  mAb  12-15,  anti-CD48  mAb HM-48, 
or anti-CD2  mAb  12-15  in combination with  either anti- 
IL-4 (22) or anti-IL-10 mAb (23)  (Table 1). 2 and 4 wk af- 
ter  the  beginning  of the  experiments,  mice  injected  with 
HgC12  (group  II)  or  with  HgC12  and  control  reagents 
(groups Ill-V) had a significant increase in total serum IgG 
(data not  shown),  IgG1  (Fig.  1 A),  and,  to  a lesser extent, 
IgG2a (Fig.  1 B) with respect to naive mice  (group  I). IgE 
levels were  augmented  60-  and 34-fold at 2  and  4 wk,  re- 
spectively (Fig.  1  C). At 4 wk, all mice injected with HgC12 
and IgG or CD8 Rg had developed ANolAs  (Fig. 2). 
Spleen  tissue  sections  from mice killed  1,  3,  6,  or  12  h 
and 2, 5,  15, or 30 d after the beginning ofHgC12 injection 
were subjected to immunocytochemical analysis for IFN-% 
IL-2, and IL-4 expression.  As a positive control for IFN-~/ 
and  IL-2  expression,  skin  and  spleen  tissue  sections  of 
C57BL/10  mice, immunized 7  d previously in the footpad 
with  ovalbumin  in  CFA,  were  examined.  Consistent  with 
observations  by  others  (17),  IFN-~/-  and  IL-2-producing 
cells were identified  around dermal vessels (Fig. 3  a) and in 
the  red  pulp  of the  spleen  (Fig.  3  c),  respectively.  In con- 
trast,  IFN-~  (Fig.  3  b)  and  IL-2  (Fig.  3  d)  expression  was 
not  detectable  in  the  spleens  of mice injected  with  HgC12 
during the entire period of observation.  IL-4, on the other 
Table  1.  Experimental  Design 
Number 
Group  of mice  HgC12  Treatment 
I  7  -  None 
II  6  +  None 
III  6  +  Human IgG +  Hamster IgG 
IV  3  +  CD8 Rg 
V  6  +  Rat IgG 
VI  6  +  CTLA-4 Rg 
VII  6  +  Anti-CD40L mAb (MR1) 
VIII  6  +  CTLA-4 Rg +  Anti-CD40L 
mAb (MR1) 
IX  6  +  Anti-CD2 rnAb (RM2-1) 
X  6  +  Anti-CD2 mAb (12-15) 
XI  6  +  Anti-CD48 mAb (HM48-1) 
XII  6  +  Anti-CD2 mAb (12-15)  +  Anti-IL4 
mAb (11Bll) 
XIII  6  +  Anti-CD2 mAb (12-15)  +  Anti-ILl0 
mAb (SXC-1) 
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Figure  1.  Serum levels of lgG1 (A), IgG2a (B), and IgE (C) detected 
by ELISA at 2 and 4 wk after the beginning of the experiments. Data are 
shown as means +  SD. Control groups II-V showed comparable results. 
Statistical analysis was performed between  group  II and groups VI-XI 
('P <0.05). 
hand,  was visualized in the periarteriolar lymphoid sheaths 
(PALSs)  and  in  the  areas in which  PALSs merge with  the 
follicular  mantle  as  early as  1  h  after the  first  injection  of 
HgC12.  After  2  d,  IL-4  was  detected  on  the  surface  of B 
cells in the mantle and marginal zones of lymphoid follicles. 
Between  15  and 30 d  after injection,  a diffuse staining pat- O 
O  60 
,,i,,-" 
x 





2  2~ 
0 
ffl 
￿9  ~  0 
T 
I1"** 
I  II  VI  VII  VIII l 
IX  X  Xl  Xll 
Groups 
Figure 2.  Levels of circulating ANolA IgG at 4 wk measured by indi- 
rect  immunofluorescence using Hep-G2  cells.  At  day  0  and  at  2  wk, 
ANolAs were undetectable. In group II, ANolA levels were comparable 
to those of groups III-V. Data are expressed as the mean +  SD. Statistical 
analysis was performed  for  groups VI-XI,  with  group  II  values as  the 
baseline (*P <0.05). 
tern for IL-4 was observed in PALSs and in the marginal 
zones.  The number of Thyl.2  §  CD4 §  cells,  and plasma 
cells progressively increased in the red pulp during the ob- 
servation period; the germinal centers and the number of 
CD45R./B220 +  cells  in  the  follicular  mantles  were  also 
augmented. No appreciable variation in number and distri- 
bution ofCD8 § cells was observed. 
Untreated  mice  (group  I)  had  minimal  focal and  seg- 
mental  deposition  of IgG  in  the  glomerular mesangium, 
but not in  the  vasculature  (Fig.  4  a).  Mice injected with 
HgC12 alone  (group  II)  or  HgC12 and  control  reagents 
(groups Ill-V) presented with abundant mesangial deposi- 
tion of IgG in all glomeruli (Fig.  4 b). In the capillaries  of 
lung, liver, and testis, deposits of IgG were absent or mini- 
mal, and focal but granular deposits of IgG were present in 
the walls of large vessels, especially arteries, in all organs. 
CTLA4 Rg and Anti-CD40L mAb MR1 Prevent the De- 
velopment  of HgCl2-mediated  Glomerular and  Vascular Le- 
sions.  Animals treated with HgC12 and injected with 300 
txg of CTLA4 Rg on days 0, 5, and 15 (group VI) revealed 
normal serum levels of total IgG  (data  not shown),  IgG1, 
IgG2a, and IgE (Fig.  1) and undetectable levels of ANolA 
(Fig.  2)  at 2 and 4 wk.  In mice injected at the same time 
points  with  250  Ixg  of anti-CD40L  mAb  MR1  (group 
VII), serum IgG levels were normal at 2 wk and increased 
at  4  wk,  although  to  a significantly lesser degree than  in 
group II animals.  Similarly, serum IgE levels were reduced 
at  2  and  4  wk  with  respect  to  those  in  group  II  mice. 
ANolAs were detectable, at a low titer, in one mouse only. 
Treatment with  a combination of CTLA4 R.g  and MR1 
(group  VIII)  resulted  in  normal  serum  total  IgG,  IgG1, 
IgG2a,  and  IgE levels and absence  of detectable ANolAs 
during the entire duration of the study (Figs. 1 and 2). 
Splenocyte expression of IL-4, IL-2, and IFN-~/was not 
significantly different from that of group II animal counter- 
parts.  Similarly, T  and B cell populations were comparable 
to those in spleens of group I and II mice, as demonstrated 
by days  15 and 30 flow cytometry analysis of Thyl.2  + and 
CD45R/B220 + splenocytes (data  not shown).  No signifi- 
cant variation in the number of PBL was observed (data not 
shown), indicating that the effects of CTLA4 Rg and anti- 
CD40L  mAbs  were  not  due  to  lysis  of target  cells  but 
rather to abrogation of specific intercellular signals.  None 
of the animals in these three groups had vascular wall IgG 
deposits, and glomerular mesangial deposits were minimal 
or absent (Fig. 4, a, c, and d). 
Engagement of CD2 Induces an  Unusually Severe Systemic 
Immune Complex Disease in HgCl2-treated Mice.  In  mice  in- 
jected at days 0, 5, and 15 with HgC12 and 200 p~g of either 
RM2-1  (group IX)  or 12-15  anti-CD2  mAbs  (group X), 
serum IgG,  IgG1,  IgE, and ANolAs but not IgG2a levels 
were significantly augmented, in comparison with those in 
animals treated with HgC12 alone (Figs. 1 and 2). Immuno- 
histochemical  analysis  of  the  spleens  of  these  animals 
showed an absence of detectable IFN-y and IL-2, in con- 
trast with markedly enhanced IL-4 expression (visible  6 h 
after HgC12/anti-CD2 mAb injection) in comparison with 
that observed in mice treated with HgC12 only (Fig.  3, g 
and h). 
Abundant,  diffuse  granular  deposits  of IgG  were  ob- 
served  by  immunofluorescence in  the  mesangium  of all 
glomeruli and in the basal part of proximal, distal, and col- 
lecting tubules  (Fig.  5  a).  Similar deposition  of lgG  was 
detected in the alveolar (Fig. 5 c) and cardiac (Fig. 5 a  t) cap- 
illaries, sinusoids,  basement membranes of seminiferous tu- 
bules, and arteries and veins of all of the organs examined. 
Moreover, mouse IgG was found in cardiac myofibrils and 
along the Z  lines (Fig.  5  d and its inset).  By electron mi- 
croscopy, dense deposits were seen in the mesangial matrix 
(Fig.  5  b)  and along the basement membranes and matrix 
between  smooth  muscle  cells  in  the  arteries  (data  not 
shown). Anti-CD48  mAbs  did not alter the development 
of the disease as assessed by the serological and immunohis- 
tological findings (data not shown). 
To determine whether the effect on disease development 
of anti-CD2  antibodies  was  primarily  due  to  Th2  cell- 
derived  cytokines,  IL-4  and  IL-10,  two  groups  of mice 
were injected with anti-CD2 mAb 12-15 on days 0, 5, and 
15, together with either 200 tzg per injection of anti-IL-4 
mAb  11Bll  (22)  or anti-IL-10  mAb  SXC-1  (23).  Anti- 
IL-4 mAb partially reduced the ANolA titers in all of the 
animals (Fig. 2) and IgG deposits in renal and extrarenal tis- 
sues in two out of six mice (data not shown). The total IgG 
and  IgE  titers  remained  comparable  to  those  in  animals 
treated with ~nAb 12-15  alone.  Anti-IL-10  mAb  had no 
effect on any of  the anti-CD2 mAb-induced disease param- 
eters (data not shown). 
Discussion 
In the present study, we have shown that an imbalance 
between Thl  and Th2 population cytokine production is 
1476  Lymphocyte Costimulation and Th2-mediated Disease Figure 3.  Cytokine production in the skin and the spleen assessed  by in situ immunocytochemistry. (a) IFN-~/production by cells (brown color) infiltrat- 
ing the skin of a mouse 7 d after local immunization with OVA in CFA. (b) Absence of IFN-~/+ cells in the spleen of a mouse 30 d after the beginning of 
injections ofHgC12. (c) IL-2  + cells (light brown) in the spleen of a mouse 7 d after immunization with OVA, as described in (a). (d) Absence oflL-2 + cells 
in the spleen of a mouse 30 d after injection of HgC12.  (e) IL-4  §  cells (light brown) in the PALS region 6  h  after injection of HgC12;  at the periphery of 
PALSs, IL-4 overlaps with CD45R/B220 + cells (blue). ~  IL-4  + (brown) and CD45R/B220 + (blue) cells in the red pulp of a mouse 30 d after injection of 
HgC12.  (g) IL-4 + splenocytes 6 h after injection ofHgC12. (h) IL-4  + splenocytes 6 h after injection ofHgC12 and anti-CD2 mAb 12-15.  ￿  (a, b, d, g, 
and h);  ￿  (c and e). 
1477  Biancone et al. Figure 4.  Immunofluorescence  microscopy  ofglomenllar and vascular  lesions. (a) Minimal and focal deposition  of mouse IgG (+) in mesangium  of a 
naive SJL mouse (group I). IgGs are absent in the tubules and in the walls of an artery (lower right). (b) Renal tissues from an SJL mouse injected with 
HgC12 and killed at day 30 (group II). Moderate deposition  of IgG (+ +) in the mesangium  and in the walls of arterioles. Minimal and segmental  deposi- 
tion oflgG (+) in the mesangium  of SJL mouse injected with (c) HgC12 and CTLA4 Rg (group VI), and (d) HgC12 and MR1 mAb (group VII). (e) By 
electron microscopy, the mesangium  of a mouse from group VII appears normal. ￿  (a-d); ￿  (e). 
associated  with  HgC12-induced  disease  and  that  soluble 
CTLA4 Rg and anti-CD40L mAb, alone or in combina- 
tion, prevent the development of HgC12-induced autoim- 
mune glomerular and vascular lesions in mice. In contrast, 
two different anti-CD2 antibodies that have been shown to 
exert an inhibitory effect on lymphocyte activation in vitro 
(8, 24) and in vivo (10,  11, 25) markedly enhanced the au- 
toimmune manifestations and induced an unusually severe 
systemic immune complex disease. 
The  inhibition of the  disease by anti-CD40L antibody 
and CTLA4 Rg treatment underscores the  importance of 
physical T  cell-B cell interaction and that  of the  CD40- 
CD40L  and  CTLA4/CD28-B7.1/B7.2  pathways  in  the 
generation of a Th2-mediated autoimmune process.  Inter- 
1478  Lymphocyte Costimulation and Th2-mediated Disease Figure 5.  Immunofluorescence and electron microscopy of tissues from mice injected with HgCI  2 and anti-CD2 mAb 12-15 (group X). (a) Marked 
and diffuse granular deposition of IgG (+ + + +) in the glomerular mesangium, in the walls of arterioles, and in the basal part of tubular cells. (b) Dense 
deposits in the mesangial matrix. (c and d) Marked and diffuse granular deposition of IgG (+ + + +) in the walls of alveolar capillaries  (c) and in cardiac 
capillaries,  myofibrils, and myofibril Z lines (d,  inset).  X400 (a, c, and d); ￿  (b); X700 (d,  inset). 
estingly, CTLA4  Rg failed to  inhibit ongoing production 
of IL-4, consistent with observations by others (26)  show- 
ing that CTLA4-Ig appears to have a pronounced blocking 
effect on Thl  responses but spares Th2-derived cytokines. 
Thus,  it  appears  likely that  other  costimulatory pathways 
may be implicated in  regulation of IL-4 production by T 
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cells and that IL-4 production does not suffice to induce or 
maintain HgC12-associated autoimmune disease. 
The  effects of anti-CD2 mAbs RM2-1  and  12-15  have 
been extensively studied in vitro and in vivo. RM2-1  pre- 
vents CD2-CD48  interaction (8) and inhibits T  cell activa- 
tion  (8,  24)  whereas  mAb  12-15  inhibits cytotoxic T  cell activity (10,  25)  and suppresses contact sensitivity response 
(10,  11). Moreover, administration  ofmAb  12-15 prolongs 
allograft  and  xenograft  survival  by  suppressing  Thl  re- 
sponses  (12)  and,  when  given  in  combination  with  anti- 
CD3  mAbs,  anti-CD2  ligand  (CD48)  mAbs,  or  FK506, 
enables  indefinite  graft survival  (13,  25).  In  contrast  with 
their  effects  on  Thl  activity,  we  found  anti-CD2  mAbs 
RM2-1  and  12-15  to exacerbate HgC12-associated pathol- 
ogy in  mice,  resulting  in  marked  increase  in  serum  IgG, 
IgG1, IgE, and ANolAs; IL-4 production in the spleen; and 
transformation  of a  mild mesangial  glomerulopathy  into  a 
severe systemic immune complex disease.  Thus,  these two 
anti-CD2  mAbs  enhanced  the  HgC12-mediated  Th2- 
dependent antibody response, reminiscent of their capacity 
to promote generation  of CD4 +,  IL-4-, and TGF-[3-pro- 
ducing  cells  while  suppressing  cytotoxic  T  cell  activity in 
vitro  (25),  and  to  stimulate  the  D10.G4.1  murine  Th2 
clone to produce IL-5, IL-6, and IL-10 (27). 
Recent work has shown that antibodies  directed at spe- 
cific regions of the CD2 molecule can block T  cell respon- 
siveness to APC-derived IL-12 (28). Because IL-12 promotes 
naive CD4 + cell differentiation  to the Thl  phenotype and 
stimulates  Thl  cell activity,  engagement of CD2  results in 
suppression  of  Thl  cytokine  production.  Since  Thl- 
derived cytokines inhibit Th2 function, suppression of Thl 
activity may explain, in part, the observed increase in Th2- 
type responses.  The effects of CD2 engagement,  however, 
do not appear to be solely Th2  cytokine-dependent,  since 
they  are  only  partially  attenuated  by  anti-IL-4  mAb  and 
unaffected by anti-IL-10 mAb. Therefore, additional mech- 
anisms,  possibly cell  contact  dependent,  may underlie  the 
observed CD2-mediated stimulation. 
The results of this study support the existence of a func- 
tional class of cell contact-dependent  lymphocyte costimu- 
latory pathways that determine whether any given helper T 
cell response will be of the Thl  or Th2 type. Thus,  differ- 
entiation  of Th cells toward the Thl  and Th2 phenotypes 
may be controlled by preferential interaction with B7.1- or 
B7.2-expressing  APC  (1),  whereas  CD2  derived  signals 
may selectively regulate  the  effector functions  of Thl  and 
Th2  cells,  inhibiting  Thl,  while  stimulating  Th2  activity. 
The possibility of functionally manipulating these pathways 
offers potentially powerful  approaches  to the  management 
of antibody-dependent  autoimmune disease. 
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